300119 Stock Overview
Engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 6/6 |
My Notes
Capture your thoughts, links and company narrative
Tianjin Ringpu Bio-Technology Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.24 |
| 52 Week High | CN¥21.25 |
| 52 Week Low | CN¥11.25 |
| Beta | 0.69 |
| 1 Month Change | -0.33% |
| 3 Month Change | 43.28% |
| 1 Year Change | 12.66% |
| 3 Year Change | -23.17% |
| 5 Year Change | 26.23% |
| Change since IPO | 19.74% |
Recent News & Updates
There's No Escaping Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Muted Earnings Despite A 29% Share Price Rise
Nov 26
Is There An Opportunity With Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) 42% Undervaluation?
Nov 25Recent updates
There's No Escaping Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Muted Earnings Despite A 29% Share Price Rise
Nov 26Is There An Opportunity With Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) 42% Undervaluation?
Nov 25Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)
Nov 05These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well
Oct 30The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More
Oct 08Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 26Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet
Aug 23Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly
Jun 26Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)
Apr 05Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity
Mar 28Shareholder Returns
| 300119 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.9% | -1.0% | 0.4% |
| 1Y | 12.7% | -3.0% | 12.3% |
Return vs Industry: 300119 exceeded the CN Pharmaceuticals industry which returned -3% over the past year.
Return vs Market: 300119 matched the CN Market which returned 12.3% over the past year.
Price Volatility
| 300119 volatility | |
|---|---|
| 300119 Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 300119 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300119's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,496 | Lei Xu | www.ringpu.com |
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. The company provides vaccines and drugs for poultry, waterfowl, livestock, and other animals; pet products comprising insect repellent series, ear products, nutritional supplements, anesthesia for surgery, anti-infective, antiviral, benazepril hydrochloride chewable tablets, meloxicam tablets, benzyl trimethylammonium chloride solution, etc.; and waterfowl products, including duck tempusu live/inactivated vaccine, gosling plague refined egg yolk antibody, duck infectious serositis inactivated vaccine, duck viral hepatitis refined egg yolk antibody, duck plague live vaccine, swine fever vaccine, etc. It offers ruminant products comprising cefquinome sulfate breast injection, ceftiofur hydrochloride injection, foot bath, nitrofenac injection, etc.; livestock products comprising ceftiofur injection, florfenicol powder, compound amoxicillin powder, tyvalin tartrate premix, carbasalate calcium soluble powder, florfenicol injection, etc.; and APIs comprising tilmicosin, tilmicosin phosphate, totrazuli, florfenicol, warnemulin hydrochloride, etc. In addition, the company provides potassium persulfate complex powder, concentrated glutaraldehyde solution, decyl ammonium bromide solution, and glutaraldehyde decyl ammonium bromide solution.
Tianjin Ringpu Bio-Technology Co.,Ltd. Fundamentals Summary
| 300119 fundamental statistics | |
|---|---|
| Market cap | CN¥8.41b |
| Earnings (TTM) | CN¥423.98m |
| Revenue (TTM) | CN¥2.41b |
19.8x
P/E Ratio3.5x
P/S RatioIs 300119 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300119 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.41b |
| Cost of Revenue | CN¥1.24b |
| Gross Profit | CN¥1.17b |
| Other Expenses | CN¥747.75m |
| Earnings | CN¥423.98m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 48.65% |
| Net Profit Margin | 17.60% |
| Debt/Equity Ratio | 25.7% |
How did 300119 perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield43%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 01:45 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tianjin Ringpu Bio-Technology Co.,Ltd. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jia Chen | Changjiang Securities Co. LTD. |
| Xu Qing Liu | Chasing Securities |
| Junhao Fan | China International Capital Corporation Limited |